Stoskus M - Search Results

1

Recent advances in quantitative chimerism analysis.

Gineikiene E, Stoskus M, Griskevicius L. Gineikiene E, et al. Among authors: stoskus m. Expert Rev Mol Diagn. 2009 Nov;9(8):817-32. doi: 10.1586/erm.09.66. Expert Rev Mol Diagn. 2009. PMID: 19895227 Review.

2

Single nucleotide polymorphism-based system improves the applicability of quantitative PCR for chimerism monitoring.

Gineikiene E, Stoskus M, Griskevicius L. Gineikiene E, et al. Among authors: stoskus m. J Mol Diagn. 2009 Jan;11(1):66-74. doi: 10.2353/jmoldx.2009.080039. Epub 2008 Dec 4. J Mol Diagn. 2009. PMID: 19056844 Free PMC article.

3

Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities.

Stoskus M, Gineikiene E, Valceckiene V, Valatkaite B, Pileckyte R, Griskevicius L. Stoskus M, et al. Blood Cells Mol Dis. 2011 Apr 15;46(4):321-6. doi: 10.1016/j.bcmd.2011.02.005. Epub 2011 Mar 17. Blood Cells Mol Dis. 2011. PMID: 21414819

4

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia.

Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J, Degulys A, Zvirblis T, Griskevicius L. Pileckyte R, et al. Among authors: stoskus m. Leuk Lymphoma. 2011 Jun;52(6):1055-65. doi: 10.3109/10428194.2011.562572. Leuk Lymphoma. 2011. PMID: 21599591 Clinical Trial.

5

Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability.

Giedraitiene N, Kaubrys G, Kizlaitiene R, Bagdonaite L, Griskevicius L, Valceckiene V, Stoskus M. Giedraitiene N, et al. Among authors: stoskus m. Med Sci Monit. 2015 May 26;21:1512-9. doi: 10.12659/MSM.894119. Med Sci Monit. 2015. PMID: 26009248 Free PMC article. Clinical Trial.

6

ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.

Stoskus M, Vaitkeviciene G, Eidukaite A, Griskevicius L. Stoskus M, et al. Blood Cells Mol Dis. 2016 Mar;57:30-4. doi: 10.1016/j.bcmd.2015.11.006. Epub 2015 Nov 15. Blood Cells Mol Dis. 2016. PMID: 26852652

7

The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer.

Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K. Beiša A, et al. Among authors: stoskus m. Endokrynol Pol. 2016;67(1):35-40. doi: 10.5603/EP.2016.0005. Endokrynol Pol. 2016. PMID: 26884113 Free article.

8

Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells.

Stoskus M, Eidukaite A, Griskevicius L. Stoskus M, et al. Leuk Res. 2016 Aug;47:16-21. doi: 10.1016/j.leukres.2016.05.009. Epub 2016 May 17. Leuk Res. 2016. PMID: 27239736

9

The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.

Beiša A, Kvietkauskas M, Beiša V, Stoškus M, Ostanevičiūtė E, Jasiūnas E, Griškevičius L, Strupas K. Beiša A, et al. Among authors: stoskus m. Langenbecks Arch Surg. 2017 Mar;402(2):227-234. doi: 10.1007/s00423-017-1560-2. Epub 2017 Feb 3. Langenbecks Arch Surg. 2017. PMID: 28160058

10

Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.

Beiša A, Kvietkauskas M, Beiša V, Stoškus M, Ostanevičiūtė E, Jasiūnas E, Griškevičius L, Šeinin D, Šileikytė A, Strupas K. Beiša A, et al. Among authors: stoskus m. Exp Clin Endocrinol Diabetes. 2019 Apr;127(4):247-254. doi: 10.1055/a-0588-4885. Epub 2018 Mar 22. Exp Clin Endocrinol Diabetes. 2019. PMID: 29566402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page